The Great News from Amylyx Pharmaceuticals
On Jun. 13, 2022, Amylyx Pharmaceuticals (AMLX) announced that Health Canada has approved ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine), with conditions, for amyotrophic lateral sclerosis (ALS).
The important thing to learn from Amylyx Pharmaceuticals' press release is that the clinical data demonstrated a . . .
This content is for paid subscribers.
Impacting News
June 23, 2022
